Sentences with phrase «therapy product developed»

Not exact matches

And Xenon, a Vancouver - based biotech, completed a US$ 31 - million private equity financing last April that will allow it to further develop its product pipeline, which consists of small - molecule therapies for select neurological, cardiovascular and metabolic diseases.

Biosimilars» burgeoning popularity has fostered some intriguing partnerships as companies try to create new, innovative biologic therapies, defend their existing products from sales slumps, and develop biosimilars to eat into competitors» branded biologics sales.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

In my research to find therapies and equipment to help her develop fully, I came across a product called theratogs.

However, BAC maintains that «researchers should not be prohibited from gaining commercially from the products of research, as well as treatments and therapies developed from the donated materials.»

Researchers should not be prohibited from gaining commercially from the products of research, as well as treatments and therapies developed from the donated materials.

We have developed leading products within diabetes care, haemophilia, growth hormone therapy and hormone replacement therapy.

On 1 May 2002, CNPR incorporated to become MerLion Pharmaceuticals, a home - grown Singapore drug discovery company that aims to develop new drugs for human therapy from natural product leads.

Should the project find specific bacteria, this would open the prospect of developing preventive therapies through vaccines or probiotic additives to food products.

Whether it's developing new products that will be manufactured in America, or getting and using energy more sustainably, or improving health care with better therapies and better use of information technology, or providing better protection for our troops abroad and our citizens at home, innovation will be key to our success.

The report, which included a recommendation on advancing regenerative cellular therapies, proposed a series of viable legislative actions that Congress could take to help streamline the process by which safe and effective medical products are developed and delivered to patients.

Supported by: Hear from leading expert Dr David DiGiusto, Stanford University School of Medicine, USA, as he shares his extensive experience in developing and optimizing manufacturing processes for cell and gene therapy products including:

In 1998 he co-founded Amsterdam Molecular Therapeutics (AMT; currently Uniqure), a gene therapy company that develops AAV - based gene therapy products.

American Society of Gene and Cell Therapy Annual Meeting Speaker: Olivia Kelly, Ph.D., Senior Director, Cell Biology Presentation: Developing a Cell Therapy Combination Product for Diabetes Date / Time: May 16, 8:30 AM EDT Location: Hilton Chicago, Chicago

This will fast - track new immune - modulating therapies for cancer patients by discovering and developing small molecule product candidates against immuno - oncology targets.

To deliver a functional cure for all patients with type 1 diabetes and an important new therapy for patients with type 2 disease that require insulin to maintain control, ViaCyte is developing products with numerous advantages including a virtually unlimited supply of cells manufactured under quality - controlled conditions, and a potentially safer and more optimal route of administration.

By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.

We entered into an agreement with Bayer to research, develop and commercialize AAV gene therapy products for treatment of hemophilia A.

In addition, the funding will be used to support other operations including the continued development of the PEC - Encap ™ product candidate, ViaCyte's stem cell - derived islet replacement therapy that is being developed as a treatment for all diabetes patients who require insulin to control their disease.

The idea there is that by identifying genes that cause, or contribute to glaucoma, and understanding what the protein products of those genes do, we can use new techniques to target those proteins to develop therapies that actually approach the actual disease mechanisms that cause the disease.

Wyss researchers are developing innovative new engineering solutions for healthcare, energy, architecture, robotics, and manufacturing that are translated into commercial products and therapies through collaborations with clinical investigators, corporate alliances, and formation of new startups.

Developing methods to deliver cells and to reduce contamination of hESC - derived product preparations are major concerns impacting the development and application of stem cell therapies,» said Emmanuel Baetge, Ph.D., Senior Vice President and Chief Scientific Officer of Novocell.

Diabetes Forecast highlighted ViaCyte's first - of - a-kind islet cell replacement therapy in an article discussing twelve innovative products being developed to treat and manage type 1 diabetes.

Since its beginning in the pioneering work of veterinary nutritionist and founder Dr. Mark Morris Sr. in 1939, Hill's has taken a consistent, scientific approach to developing nutritional therapies and wellness products for dogs and cats.

Do not give more potassium bromide to a groggy pet, even if the next dose is due Excess thirst, drinking and urination Giving potassium bromide with food should alleviate gastrointestinal irritation (nausea, vomiting) Lack of appetite, rashes, diarrhea, constipation Dogs may develop a cough (which resolves) when potassium bromide is discontinued Bromide levels will need to be monitored periodically to ensure they are not too high It is important to stop therapy and contact your veterinarian immediately if you think your pet has a medical problem or side effect from this product's therapy Can this drug be given with other drugs?

Vomiting, diarrhea, loss of appetite, facial swelling Joint inflammation (arthritis, fever, muscle soreness), especially in Dobermans Skin rashes and itchiness Liver failure (nausea; yellowing of gums, skin, eyes) Inability to produce adequate tears or «dry eye» (increased blinking or discharge, eye rubbing) Sulfa bladder or kidney stones Blood abnormalities (bleeding tendencies, pale gums, fatigue, or fever of 103 - 105 ° F) Dogs can develop hypothyroidism with long - term use It is important to stop therapy and contact your veterinarian immediately if you think you pet has a medical problem or side effect from this product's therapy Can this drug be given with other drugs?

Determined they could offer a «better product,» Ms. Berger and Ms. Jurgle developed the highest evaluation and certification standards in the nation for volunteer pet therapy.

Alachua, Fla. - based AGTC is a clinical - stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe inherited orphan diseases in ophthalmology.

PROFESSIONAL EXPERIENCE Senior Infusion Therapy Specialist — B. Braun Medical, New Orleans, LA / Bethlehem, PA 2005 — Present Aggressively promote pharmacy products including specialty nutrition, base nutrition, pharmacy devices, CAPS, disposable products, IV sets, NeedleFree, IV Catheters, Infusion Pumps and Pharmacy products, and drug delivery systems, by client relations initiatives, and developing new prospects.

Developed by aesthetician Kerry Benjamin, StackedSkincare ™ takes her innovative approach to skin therapy from her spa to products you can use at home.

The Sacred Soul Holistics brand endeavor to introduce and develop high quality complementary and alternative therapy products for both therapists and home users alike.